BiotechTube

V120083 + Naproxen + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteo Arthritis Knee

Conditions

Osteo Arthritis Knee

Trial Timeline

Mar 14, 2017 → Nov 21, 2017

NCT ID
NCT03028870

About V120083 + Naproxen + Placebo

V120083 + Naproxen + Placebo is a phase 2 stage product being developed by Shionogi for Osteo Arthritis Knee. The current trial status is completed. This product is registered under clinical trial identifier NCT03028870. Target conditions include Osteo Arthritis Knee.

What happened to similar drugs?

20 of 20 similar drugs in Osteo Arthritis Knee were approved

Approved (20) Terminated (0) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅raloxifene + PlaceboEli LillyApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅raloxifene + placeboEli LillyApproved
✅Capsaicin Topical SolutionAstellas PharmaApproved
✅MENATETRANONEEisaiApproved
✅Menatetrenone (Vitamin K2)EisaiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03028870Phase 2Completed

Competing Products

20 competing products in Osteo Arthritis Knee

See all competitors
ProductCompanyStageHype Score
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
ENZ215 + ProliaAlkem LaboratoriesPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Teriparatide + Alendronate Sodium + Placebo + PlaceboEli LillyPhase 3
40
TeriparatideEli LillyPhase 3
40
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
40
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
raloxifene + PlaceboEli LillyApproved
43
Subcutaneous Teriparatide + Transdermal TeriparatideEli LillyPhase 2
35
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
22
Duloxetine + Sugar pillEli LillyApproved
43
raloxifene + placeboEli LillyApproved
43
Teriparatide + Salmon CalcitoninEli LillyPhase 3
40
ForteoEli LillyPre-clinical
22
arzoxifene + PlaceboEli LillyPhase 2
35
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
UBX0101 or placeboUnity BiotechnologyPre-clinical
8